Please enable JavaScript to continue using this application.

Compare $TNGX vs $VCYT | Chartloom

Compare

$TNGX vs $VCYT

Tango Therapeutics Inc · Veracyte Inc

TNGX

Tango Therapeutics Inc

VCYT

Veracyte Inc

Compare $TNGX vs $VCYT

Comparing Tango Therapeutics Inc and Veracyte Inc

TNGXTango Therapeutics Inc

VCYTVeracyte Inc

TNGXTango Therapeutics Inc

Market cap

$3.87B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

121.5%

YTD performance

166.6%

52W performance

244.6%

FCF yield

-3.7%

VCYTVeracyte Inc

Market cap

$3.61B

P/E (TTM)

32.42x

Forward P/E (NTM)

24.66x

Forward P/S (NTM)

5.69x

Rev growth (TTM)

17.3%

YTD performance

6.7%

52W performance

28.9%

FCF yield

4.6%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

TNGX

VCYT

Detailed metrics comparison

TNGX

Tango Therapeutics Inc

VCYT

Veracyte Inc

Market Cap

TNGX$3.87B

VCYT$3.61B

Enterprise Value

TNGX$3.52B

VCYT$3.31B

Price

TNGX$23.81

VCYT$45.23

P/E Ratio

TNGXN/A

VCYT32.42x

P/S Ratio

TNGX71.83x

VCYT6.42x

EV/Sales

TNGX65.41x

VCYT5.89x

EV/EBITDA

TNGX0.00x

VCYT24.67x

P/B Ratio

TNGX3.82x

VCYT2.65x

P/FCF Ratio

TNGXN/A

VCYT21.74x

EV/FCF

TNGX-24.40x

VCYT19.94x

PEG Ratio

TNGXN/A

VCYT0.10x

Forward P/E (NTM)

TNGXN/A

VCYT24.66x

Forward P/S (NTM)

TNGXN/A

VCYT5.69x

Revenue (TTM)

TNGX$54M

VCYT$562M

Revenue Growth (YoY)

TNGX121.5%

VCYT17.3%

Forward Rev Growth

TNGX732.8%

VCYT11.4%

Gross Margin (TTM)

TNGX0.0%

VCYT71.7%

Operating Margin (TTM)

TNGX0.0%

VCYT19.6%

EBITDA Margin (TTM)

TNGX-249.8%

VCYT22.5%

Net Margin (TTM)

TNGX-229.9%

VCYT20.4%

FCF Margin (TTM)

TNGX-268.1%

VCYT29.5%

Net Income (TTM)

TNGX$-124M

VCYT$114M

FCF (TTM)

TNGX$-144M

VCYT$166M

EPS (TTM)

TNGX-$0.83

VCYT$1.40

ROE (TTM)

TNGX-2574.0%

VCYT8.6%

ROA (TTM)

TNGX-2336.0%

VCYT8.0%

ROIC (TTM)

TNGX-2574.0%

VCYT8.6%

Cash

TNGX$346M

VCYT$300M

Debt

TNGX$0

VCYT$0

Net Cash/Debt

TNGX$346M

VCYT$300M

Current Ratio (TTM)

TNGX50.82x

VCYT9.16x

Quick Ratio (TTM)

TNGX49.95x

VCYT8.60x

Debt/Equity (TTM)

TNGX0.00x

VCYT0.00x

Debt/Assets (TTM)

TNGX0.0%

VCYT0.0%

Interest Coverage (TTM)

TNGXN/A

VCYTN/A

Net Debt/EBITDA (TTM)

TNGX0.00x

VCYT0.00x

Beta

TNGX1.18

VCYT2.00

52W Performance

TNGX244.6%

VCYT28.9%

YTD Performance

TNGX166.6%

VCYT6.7%

% from 52W High

TNGX-30.8%

VCYT-25.7%

% from 52W Low

TNGX255.9%

VCYT53.6%

Asset Turnover (TTM)

TNGX0.26x

VCYT0.39x

FCF Yield (TTM)

TNGX-3.7%

VCYT4.6%

Earnings Yield (TTM)

TNGX-3.2%

VCYT3.2%

Dividend Yield (TTM)

TNGXN/A

VCYTN/A

Rule of 40

TNGX-146.6

VCYT46.8

EV/GP/RG

TNGXN/A

VCYT0.60

Ticker research

View TNGX research View VCYT research

Metric	TNGX Tango Therapeutics Inc	VCYT Veracyte Inc
Market & Valuation
Market Cap	$3.87B	$3.61B
Enterprise Value	$3.52B	$3.31B
Price	$23.81	$45.23
P/E Ratio	N/A	32.42x
P/S Ratio	71.83x	6.42x
EV/Sales	65.41x	5.89x
EV/EBITDA	0.00x	24.67x
P/B Ratio	3.82x	2.65x
P/FCF Ratio	N/A	21.74x
EV/FCF	-24.40x	19.94x
PEG Ratio	N/A	0.10x
Forward P/E (NTM)	N/A	24.66x
Forward P/S (NTM)	N/A	5.69x
Revenue & Growth
Revenue (TTM)	$54M	$562M
Revenue Growth (YoY)	121.5%	17.3%
Forward Rev Growth	732.8%	11.4%
Profitability
Gross Margin (TTM)	0.0%	71.7%
Operating Margin (TTM)	0.0%	19.6%
EBITDA Margin (TTM)	-249.8%	22.5%
Net Margin (TTM)	-229.9%	20.4%
FCF Margin (TTM)	-268.1%	29.5%
Net Income (TTM)	$-124M	$114M
FCF (TTM)	$-144M	$166M
EPS (TTM)	-$0.83	$1.40
ROE (TTM)	-2574.0%	8.6%
ROA (TTM)	-2336.0%	8.0%
ROIC (TTM)	-2574.0%	8.6%
Financial Health
Cash	$346M	$300M
Debt	$0	$0
Net Cash/Debt	$346M	$300M
Current Ratio (TTM)	50.82x	9.16x
Quick Ratio (TTM)	49.95x	8.60x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.18	2.00
52W Performance	244.6%	28.9%
YTD Performance	166.6%	6.7%
% from 52W High	-30.8%	-25.7%
% from 52W Low	255.9%	53.6%
Efficiency & Yields
Asset Turnover (TTM)	0.26x	0.39x
FCF Yield (TTM)	-3.7%	4.6%
Earnings Yield (TTM)	-3.2%	3.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-146.6	46.8
EV/GP/RG	N/A	0.60
Ticker research	View TNGX research	View VCYT research

Valuation

P/E Ratio

VCYT

32.42x

P/S Ratio

VCYT

6.42x

TNGX

71.83x

EV/FCF

TNGX

-24.40x

VCYT

19.94x

Growth & revenue

Revenue Growth TTM

TNGX

121.5%

VCYT

17.3%

Forward Revenue Growth

TNGX

732.8%

VCYT

11.4%

Profitability & performance

Gross Margin

VCYT

71.7%

TNGX

0.0%

ROE

VCYT

8.6%

TNGX

-2574.0%

FCF Yield %

VCYT

4.6%

TNGX

-3.7%

52-Week Performance

TNGX

244.6%

VCYT

28.9%

Detailed metrics comparison

TNGX

Tango Therapeutics Inc

VCYT

Veracyte Inc

Market Cap

TNGX$3.87B

VCYT$3.61B

Enterprise Value

TNGX$3.52B

VCYT$3.31B

Price

TNGX$23.81

VCYT$45.23

P/E Ratio

TNGXN/A

VCYT32.42x

P/S Ratio

TNGX71.83x

VCYT6.42x

EV/Sales

TNGX65.41x

VCYT5.89x

EV/EBITDA

TNGX0.00x

VCYT24.67x

P/B Ratio

TNGX3.82x

VCYT2.65x

P/FCF Ratio

TNGXN/A

VCYT21.74x

EV/FCF

TNGX-24.40x

VCYT19.94x

PEG Ratio

TNGXN/A

VCYT0.10x

Forward P/E (NTM)

TNGXN/A

VCYT24.66x

Forward P/S (NTM)

TNGXN/A

VCYT5.69x

Revenue (TTM)

TNGX$54M

VCYT$562M

Revenue Growth (YoY)

TNGX121.5%

VCYT17.3%

Forward Rev Growth

TNGX732.8%

VCYT11.4%

Gross Margin (TTM)

TNGX0.0%

VCYT71.7%

Operating Margin (TTM)

TNGX0.0%

VCYT19.6%

EBITDA Margin (TTM)

TNGX-249.8%

VCYT22.5%

Net Margin (TTM)

TNGX-229.9%

VCYT20.4%

FCF Margin (TTM)

TNGX-268.1%

VCYT29.5%

Net Income (TTM)

TNGX$-124M

VCYT$114M

FCF (TTM)

TNGX$-144M

VCYT$166M

EPS (TTM)

TNGX-$0.83

VCYT$1.40

ROE (TTM)

TNGX-2574.0%

VCYT8.6%

ROA (TTM)

TNGX-2336.0%

VCYT8.0%

ROIC (TTM)

TNGX-2574.0%

VCYT8.6%

Cash

TNGX$346M

VCYT$300M

Debt

TNGX$0

VCYT$0

Net Cash/Debt

TNGX$346M

VCYT$300M

Current Ratio (TTM)

TNGX50.82x

VCYT9.16x

Quick Ratio (TTM)

TNGX49.95x

VCYT8.60x

Debt/Equity (TTM)

TNGX0.00x

VCYT0.00x

Debt/Assets (TTM)

TNGX0.0%

VCYT0.0%

Interest Coverage (TTM)

TNGXN/A

VCYTN/A

Net Debt/EBITDA (TTM)

TNGX0.00x

VCYT0.00x

Beta

TNGX1.18

VCYT2.00

52W Performance

TNGX244.6%

VCYT28.9%

YTD Performance

TNGX166.6%

VCYT6.7%

% from 52W High

TNGX-30.8%

VCYT-25.7%

% from 52W Low

TNGX255.9%

VCYT53.6%

Asset Turnover (TTM)

TNGX0.26x

VCYT0.39x

FCF Yield (TTM)

TNGX-3.7%

VCYT4.6%

Earnings Yield (TTM)

TNGX-3.2%

VCYT3.2%

Dividend Yield (TTM)

TNGXN/A

VCYTN/A

Rule of 40

TNGX-146.6

VCYT46.8

EV/GP/RG

TNGXN/A

VCYT0.60

Ticker research

View TNGX research View VCYT research

Metric	TNGX Tango Therapeutics Inc	VCYT Veracyte Inc
Market & Valuation
Market Cap	$3.87B	$3.61B
Enterprise Value	$3.52B	$3.31B
Price	$23.81	$45.23
P/E Ratio	N/A	32.42x
P/S Ratio	71.83x	6.42x
EV/Sales	65.41x	5.89x
EV/EBITDA	0.00x	24.67x
P/B Ratio	3.82x	2.65x
P/FCF Ratio	N/A	21.74x
EV/FCF	-24.40x	19.94x
PEG Ratio	N/A	0.10x
Forward P/E (NTM)	N/A	24.66x
Forward P/S (NTM)	N/A	5.69x
Revenue & Growth
Revenue (TTM)	$54M	$562M
Revenue Growth (YoY)	121.5%	17.3%
Forward Rev Growth	732.8%	11.4%
Profitability
Gross Margin (TTM)	0.0%	71.7%
Operating Margin (TTM)	0.0%	19.6%
EBITDA Margin (TTM)	-249.8%	22.5%
Net Margin (TTM)	-229.9%	20.4%
FCF Margin (TTM)	-268.1%	29.5%
Net Income (TTM)	$-124M	$114M
FCF (TTM)	$-144M	$166M
EPS (TTM)	-$0.83	$1.40
ROE (TTM)	-2574.0%	8.6%
ROA (TTM)	-2336.0%	8.0%
ROIC (TTM)	-2574.0%	8.6%
Financial Health
Cash	$346M	$300M
Debt	$0	$0
Net Cash/Debt	$346M	$300M
Current Ratio (TTM)	50.82x	9.16x
Quick Ratio (TTM)	49.95x	8.60x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.18	2.00
52W Performance	244.6%	28.9%
YTD Performance	166.6%	6.7%
% from 52W High	-30.8%	-25.7%
% from 52W Low	255.9%	53.6%
Efficiency & Yields
Asset Turnover (TTM)	0.26x	0.39x
FCF Yield (TTM)	-3.7%	4.6%
Earnings Yield (TTM)	-3.2%	3.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-146.6	46.8
EV/GP/RG	N/A	0.60
Ticker research	View TNGX research	View VCYT research